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Abstract
Recent data have implicated the melanocortin (MC) system in modulating voluntary ethanol
consumption. Administration of melanotan-II (MTII), a nonselective melanocortin receptor
(MCR) agonist, reduces voluntary ethanol consumption in C57BL/6J mice. Previous studies have
demonstrated that central infusion of MTII effectively reduced voluntary ethanol drinking in
mutant mice lacking normal expression of MC3R (MC3R−/− mice) but failed to alter ethanol
drinking in mice lacking expression of MC4R, demonstrating that central MTII administration
reduces voluntary ethanol drinking by signaling through the MC4R. However, evidence shows
that the neurocircuitry recruited during excessive binge-like ethanol drinking versus moderate
ethanol drinking are not identical. Thus the present study sought to investigate the potential role of
the MC3R in binge-like ethanol intake. To this end, the “drinking in the dark” (DID) procedure, a
commonly used animal model of binge-like ethanol drinking, was employed. Wild-type MC3R+/+
and MC3R−/− mice were given intracerebroventricular (i.c.v.) infusion of MTII (0.0, 0.25, 0.50, or
1.0 μg) prior to the onset of a four-hour testing period in which mice were given access to 20% (v/
v) ethanol. Immediately after the four-hour testing period, tail blood samples were collected from
each animal in order to assess blood ethanol concentrations (BECs). Consistent with previous
findings, central administration of MTII blunted binge-like ethanol drinking in both MC3R+/+ and
MC3R−/− mice. Interestingly, all doses of MTII blunted binge-like ethanol drinking in MC3R−/−
mice during the first hour of testing, while only the 1.0 μg dose reduced binge-like drinking in
MC3R+/+ mice. Thus, MC3R−/− mice were more sensitive to the protective effects of MTII. These
data suggest that MC3Rs oppose the protective effects of MTII against binge-like ethanol
drinking, and thus selective MC3R antagonists may have potential therapeutic roles in treating
excessive ethanol drinking.
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The melanocortin (MC) peptides, α-, β-, γ- melanocyte stimulating hormone (MSH), and
adrenocorticotropic hormone (ACTH), are produced centrally by proopiomelanocortin
(POMC)-expressing neurons within the arcuate nucleus of the hypothalamus, the nucleus of
the solitary tract, and medulla (Jacobowitz and O'Donohue, 1978). These peptides, as well
as their endogenous antagonists, agouti and agouti-related protein (AgRP), act through five
seven-transmembrane G-protein coupled melanocortin receptor (MCR) subtypes. The MCRs
within the rodent brain are predominantly comprised of the MC3R and MC4R subtypes,
while MC1R, MC2R, and MC5R are expressed primarily in the periphery (Adan and
Gispen, 1997; Barrett et al., 1994; Xia et al., 1995). Together, these ligands and their
associated receptors, collectively referred to as the MC system, regulate a myriad of
physiological functions including pigmentation (Robbins et al., 1993), sexual function
(Argiolas et al., 2000), and appetite regulation (Fan et al., 1997; Giraudo et al., 1998),
among others.
A growing body of literature has also implicated MCR signaling in modulating ethanol
consumption. This association was first uncovered when it was reported that ethanol naïve
alcohol preferring rats displayed abnormal expression of MC3R and MC4R within the
nucleus accumbens and hypothalamus relative to their non-preferring counterparts
(Lindblom et al., 2002). Extending on these findings, it was later demonstrated that central
infusion of a nonselective MCR agonist, melanotan-II (MTII), attenuated voluntary ethanol
consumption in these preferring rats (Ploj et al., 2002). Furthermore, central infusion of
MTII reduced voluntary ethanol drinking in both wild-type and mutant mice deficient in
MC3R, suggesting that the MC3R does not modulate voluntary drinking (Navarro et al.,
2005). What is more, Navarro and colleagues also showed that a selective MC4R agonist
blunted voluntary ethanol consumption in wild-type C57BL/6J mice, implicating the MC4R
in modulating ethanol intake (Navarro et al., 2003). Consistent with these findings, later
work revealed that MTII had no effect on voluntary ethanol consumption in mutant mice
lacking MC4R (Navarro et al., 2011). Taken together, these data suggest that central MTII
reduces voluntary ethanol drinking by signaling through the MC4R, but not the MC3R.
However, previous findings have implicated that the MC3R regulates the transmission of α-
MSH from POMC neurons. Specifically, the MC3R has been found to be expressed on
POMC neurons (Bagnol et al., 1999), suggesting that it functions as an autoreceptor.
Subsequent in vitro investigations revealed that activation of these receptors using the
selective MC3R agonist, D-Trp8-γ-MSH, induced a marked increase in IPSC frequency on
POMC neurons (Cowley et al., 2001). Additionally, central infusions of this same
compound caused a downregulation of POMC mRNA levels in rats (Lee et al., 2008). What
is more, rats receiving intracerebroventricular (i.c.v.) infusions of an MC3R agonist
displayed increased food intake, while low doses of an MC3R antagonist reduced food
intake (Lee et al., 2008). Together, these studies provide converging evidence that indicate
the MC3R serves as an inhibitory autoreceptor on POMC neurons.
Additionally, recent converging evidence has suggested that different neurocircuitry
modulates moderate level ethanol drinking versus excessive binge-like ethanol drinking
(Lowery et al., 2010; Lowery-Gionta et al., 2012; Sparta et al., 2008). Despite the growing
body of literature implicating the MC system in voluntary ethanol consumption, the role of
the MC system in binge-like ethanol consumption remains relatively unexplored. We
recently showed that mutant mice lacking AgRP exhibited blunted binge-like ethanol
drinking, providing initial evidence that MCR signaling modulates binge-like drinking
(Navarro et al., 2009). To further characterize the role of MC system in binge-like ethanol
drinking, we employed “drinking in the dark” (DID) procedures and used mutant mice
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lacking the MC3R (MC3R−/− mice) and their wild-type counterparts (MC3R+/+ mice) in the
current study to determine the potential contribution of the MC3R in modulating the
protective effects of MTII against binge-like ethanol drinking. Consistent with the previous
data (Navarro et al., 2005), we found that infusions of MTII attenuated binge-like ethanol
consumption in both MC3R+/+ and MC3R−/− mice. However, we observed that MTII was
more effective in reducing binge-like ethanol drinking in MC3R−/− relative to MC3R+/+
mice. These data suggest that MC3Rs oppose the protective effects of MTII against binge-
like ethanol drinking, and thus selective MC3R antagonists may have potential therapeutic
value in treating excessive ethanol drinking.
2. Materials and methods
2.1. Animals
The generation of MC3R−/− has been described previously (Chen et al., 2000). Sixteen
littermate knockout (MC3R−/−) and ten wild-type (MC3R+/+) mice maintained on a C57BL/
6J background were bred in-house from heterozygous stock. Genotype was determined via
polymerase chain reaction (PCR). All mice were housed in individual home cages located in
a vivarium with an ambient temperature of approximately 22°C and a 12:12 h reverse light/
dark cycle with lights off at 7:00am. Food and water were available ad libitum except where
indicated below. It has previously been demonstrated that compounds targeting MCRs
exhibit similar effects on ethanol intake in male and female mice (Navarro et al., 2005);
therefore, both sexes were included in the present study in an effort to increase sample sizes.
All procedures in this study were in compliance with the National Institute of Health
guidelines, and all protocols were approved by the University of North Carolina Institutional
Animal Care and Use Committee.
2.2. Cannulation Surgery and Infusion Procedure
Prior to testing, mice underwent cannulation surgery targeting the left lateral ventricle,
which has been described previously (Navarro et al., 2011, 2005, 2003). Following surgery,
mice were given approximately one week to recover before testing. Following completion of
testing, cannula placement was verified histologically. All mice in the current study were
found to have accurate placement; thus no animals were excluded from the analysis due to
poor cannula placement. The non-selective MCR agonist melanotan-II (MTII; American
Peptide Company, Sunnyvale, CA) was dissolved in 0.9% saline to reach the desired
concentration (0.0, 0.25, 0.5, or 1.0 μg). A non-selective, rather than selective, MCR
compound was chosen for this study in order to elucidate the potential interaction of the
MC3R and MC4R in modulating the effects of a MCR agonist on binge-like ethanol
drinking behavior. All doses were infused in a 1.0 μl volume using a Hamilton syringe
(Hamilton Company USA, Reno, NV), which was administered manually over the course of
one minute. This injector was left in place for an extra 30 seconds to allow for diffusion and
to prevent reflux of the compound up the cannula tract. Following the infusion, mice were
returned to their homecages.
2.3. “Drinking in the dark” procedures
A four day DID procedure was used to model binge-like ethanol drinking (Rhodes et al.,
2005). It has previously been shown that mice in this paradigm are able to achieve a blood
ethanol concentrations (BECs) that surpass the 80 mg/dl criterion used by the National
Institute on Alcohol Abuse and Alcoholism to define an episode of binge drinking (National
Institute on Alcohol Abuse and Alcoholism, 2004; Rhodes et al., 2007) and that drinking
using this method is likely not motivated by caloric need (Lyons et al., 2008). For the first
three days of DID, MC3R+/+ and MC3R−/− mice were weighed and given mock infusions at
the beginning of the dark cycle in order to acclimate the animals to the infusion procedure.
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Using standard DID procedures outlined by Rhodes and colleagues (2005), water bottles
were removed three hours into the dark cycle and replaced with a single bottle of ethanol
(20% v/v) for two hours. Water bottles were returned to the mice at the end of each day of
testing. Treatment groups were equated based on ethanol consumption on days 1–3. On the
fourth day of DID, mice were infused with a 0.0, 0.25, 0.5 or 1.0 μg dose of MTII as
described above. Although it has previously been reported to have a relatively short half-life
(Ugwu et al., 1994) in rats, the detailed pharmacokinetics of MTII have yet to be explored in
mice. Nonetheless, previous studies have demonstrated that its effects on ethanol
consumption persist for several hours following initial administration. For example, Navarro
and colleagues (2003) observed that a single injection of MTII blunted ethanol drinking as
long as eight hours post-injection. Binge-like ethanol consumption was assessed on this
fourth day of testing, which followed the same schedule as the first three days with the
exception that ethanol access was extended to four hours. MC3R+/+ and MC3R−/− mice
were given i.c.v. infusions of MTII two hours before ethanol access. Consumption measures
were collected at the first hour of ethanol access as well as at the end of the four hours of
testing in order to measure the immediate and prolonged effects of the drug on ethanol
intake, respectively. Tail bloods were collected from each animal at the end of the four-hour
testing period in order to determine BECs using an alcohol analyzer (Analox Instruments,
Lunenburg, MA). Mice were given at least three days of rest between subsequent 4-day DID
sessions in order to avoid carryover effects of the drug. A Latin square design was utilized
such that the animals received each dose (vehicle, 0.25, 0.5, and 1.0 μg of MTII) in a
counterbalanced order.
2.4 Statistical analysis
A repeated measures ANOVA was used to analyze consumption and BEC data, with dose of
MTII (0, 0.25, 0.5, or 1.0 μg) as the within-subject variable and genotype (MC3R−/− and
MC4R+/+) as the between-subject variable. The tail blood samples from three MC3R−/−
mice were lost during centrifugation and were eliminated from BEC analysis. Importantly,
the central issue regarding the role of the MC3R in modulating the protective effects of
MTII against binge-like ethanol drinking was directly assessed using planned comparisons
(Cohen, 2008) based on a priori predictions stemming from previous observations.
Specifically, given the previous research indicating that MTII blunts ethanol drinking
(Navarro et al., 2011, 2005, 2003; Ploj et al., 2002) coupled with the implications that the
MC3R serves as an inhibitory autoreceptor on POMC neurons (Bagnol et al., 1999; Cowley
et al., 2001; Lee et al., 2008; Marks et al., 2006), we predicted that MTII would dose-
dependently blunt binge-like ethanol drinking and that this effect would be more robust in
MC3R−/− mice since a lack of presynaptic autoreceptors would protect against MTII-
induced inhibition of POMC neurons. Thus, planned comparisons were performed using
paired-sample t-tests to directly assess the effect of each dose of MTII (0.25, 0.5, or 1.0 μg)
versus vehicle treatment within each genotype. Additionally, Bonferroni corrections were
used with planned comparisons to control for inflation of Type I error rate associated with
multiple tests. Finally, a Pearson correlation was performed to examine the relationship
between ethanol consumed over the four hour test and BECs collected immediately after
ethanol testing.
3. Results
3.1. Effect of MTII on the first hour of binge-like ethanol drinking
Repeated measures ANOVA revealed that binge-like ethanol consumption during the first
hour of testing was similar between MC3R+/+ and MC3R−/− mice (main effect of genotype:
F(1, 24) = 1.499, p = 0.233; Fig. 1A). Relative to vehicle, central infusions of MTII
significantly reduced binge-like ethanol consumption during the first hour of testing among
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both MC3R+/+ and MC3R−/− mice (main effect of dose: F(3, 72) = 6.251, p = 0.001).
Specifically, ethanol drinking was significantly reduced in mice treated with the highest
dose of MTII (1.0 μg) relative to vehicle (p < .001). No significant interaction was observed
during the first hour (genotype × dose interaction: F(3, 72) = 0.993, p = 0.401). Interestingly,
among MC3R−/− mice, planned comparisons revealed that, relative to vehicle, all doses
(0.25, 0.5, and 1.0 μg) of MTII were effective in reducing ethanol intake during the first
hour (t(1,15) = 3.039, p = 0.008; t(1,15) = 4.128, p = 0.001; t(1,15) = 3.610, p = 0.003;
respectively). However, among MC3R+/+ mice, only the highest dose of MTII produced a
significant reduction in ethanol drinking (t(1,9) = 3.559, p = 0.006).
3.2. Effect of MTII on four hours of binge-like ethanol drinking
Binge-like ethanol consumption between MC3R+/+ and MC3R−/− was not significantly
different at the end of the four hour test period (main effect of genotype: F(1, 24) = 1.245, p =
0.276; Fig. 1B). Treatment with MTII elicited a significant decrease in ethanol drinking
across the four hours regardless of genotype (main effect of dose: F(3, 72) = 5.594, p =
0.002). Further examination revealed ethanol drinking was significantly reduced following
treatment with the highest dose of MTII (p = 0.002). No significant interaction effect was
observed at the end of the four hour test period (genotype × dose interaction: F(3, 72) =
0.813, p = 0.491). However, planned comparisons revealed that the significant reduction in
ethanol intake in MC3R−/− mice treated with the highest dose of MTII persisted across the
four hour test period (t(1,15) = 3.218, p = 0.006).
3.3. Effect of MTII on BEC
No significant differences in BECs between MC3R+/+ and MC3R−/− mice were observed
following DID testing (main effect of genotype: F(1, 21) = 0.126, p = 0.726; Fig. 1C). There
was a trend for an effect of dose of MTII on measured BECs, but this effect was not
significant (main effect of dose: F(3, 63) = 2.549, p = 0.064). No significant interaction was
observed in measured BECs (genotype × dose interaction: F(3, 63) = 0.812, p = 0.492).
Further analysis of the planned comparisons yielded no significant differences in either
genotype at any of the doses tested relative to the vehicle condition. Although these analyses
revealed no significant differences in BEC as a result of drug treatment, there was a strong,
positive relationship between BEC and ethanol consumed over the four hour period for both
genotypes (MC3R−/−: r(57) = 0.596, p < 0.001; MC3R+/+: r(38) = 0.631, p < 0.001).
4. Discussion
These studies examined the central actions of the nonselective MCR agonist MTII, on
binge-like ethanol drinking in MC3R−/− and wild-type MC3R+/+ mice. Overall, the present
results confirmed previous findings showing that centrally administered MTII attenuates
ethanol consumption (Navarro et al., 2011, 2005, 2003). The observations made here add to
the literature by showing that central administration of MTII also results in a decrease in
binge-like ethanol intake in both MC3R−/− and MC3R+/+ mice. Importantly, we observed
that mice with normal expression of MC3R were less sensitive to the protective effects of
MTII against binge-like ethanol drinking relative to mice deficient of MC3R. This report, to
the best of our knowledge, provides the first evidence that the MC3R modulates the actions
of centrally administered MTII on binge-like ethanol drinking.
One could argue that the increased sensitivity observed in MC3R−/− mice is due to the fact
that the removal of MC3Rs may allow for a greater proportion of MTII to interact with
MC4Rs. While we cannot completely rule out this possibility, MTII is known to be a highly
potent MC receptor agonist (Dorr et al., 1996); as such, the effects of increased binding of
MTII to MC4R in MC3R−/− mice might be expected to be negligible.
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A more likely explanation for this phenomenon is that the MC3R acts as an inhibitory
autoreceptor on POMC neurons. Previous studies have already identified MC3R as being
expressed on POMC neurons (Bagnol et al., 1999). What is more, data from
electrophysiological, immunohistochemistry, and behavioral studies report decreased
activity in POMC neurons following selective activation of MC3Rs (Cowley et al., 2001;
Lee et al., 2008; Marks et al., 2006). Although AgRP neurons within the arcuate nucleus
express MC3R (Bagnol et al., 1999), it has previously been demonstrated that central
administrations of a selective MC3R agonist suppresses levels of POMC mRNA expression
but has no effect on AgRP gene expression (Lee et al., 2008). Together, these studies
reinforce the idea that the MC3R acts as an inhibitory autoreceptor on the POMC circuit,
likely inhibiting transmission of α-MSH from POMC neurons. Thus, in the absence of the
MC3R, both MTII and endogenous α-MSH participate in tandem to reduce binge-like
ethanol drinking, while activation of the MC3R by MTII counteracts this process in wild-
type mice by inhibiting the release of endogenous α-MSH. A second possibility is that the
MC3R, in some circuits, exists as a postsynaptic receptor and functionally opposes the
downstream actions of MC4R signaling. The observation that genetic deletion of MC3R
produces a mouse that is more susceptible to the attenuating effects of MTII on binge-like
ethanol drinking is consistent with either a presynaptic autoreceptor or a postsynaptic
receptor that functionally opposes the actions of the MC4R. In terms of the current study,
both genotypes displayed reductions in binge-like ethanol drinking in response to MTII
since the intact MC4R of both genotypes was able to blunt ethanol drinking- a finding that is
consistent with the previous literature (Navarro et al., 2011, 2005). Importantly, MC3R−/−
mice showed increased sensitivity to the protective effects of MTII (i.e. significant
reductions in drinking were observed in lower doses of MTII in these mice relative to
MC3R+/+) as the oppositional MC3R was removed and MC4R was free to function
unimpeded.
The fact that no differences were found in BECs between vehicle-treated and MTII-treated
mice may be related to the time course of each animal's drinking. Specifically, tail blood
samples were collected only at the end of the 4-hour test. As such, drinking that occurs
toward the beginning of the test session may be less influential on the measured BEC than
drinking that occurs more towards the end of the session. This is especially likely
considering the rather rapid decline of BEC that is characteristic of mice (Livey et al., 2003).
As the protective effects of MTII on ethanol intake were most evident at the beginning of
the 4-hour test, it seems likely that increased consumption later in the 4-hour test session
may have masked the effects of MTII treatment on BECs. In this sense, tail blood samples
collected after the first hour may have provided a more accurate assessment of an animal's
BEC. However, taking tail bloods for BEC assessment is a stressful experience for the
animal that involves restraining the mouse and nicking its tail to obtain a blood sample to be
analyzed. Moreover, previous studies have reported that stressful stimuli can alter drinking
behavior (Nash and Maickel, 1985; Rockman et al., 1986); therefore, tail bloods were only
collected after ethanol bottles were removed in order to avoid submitting the animals to
undue stress during testing, which could have confounded the drinking data. Importantly,
although no differences were found in BECs between treatment conditions, there was a
strong, direct correlational relationship between the amount ethanol consumed and the
measured BECs for both genotypes.
It may be surprising that the observations made here differ from previous studies examining
the role of the MC3R in ethanol drinking, which found no significant contribution of the
MC3R on ethanol drinking (Navarro et al., 2005). However, two key differences between
the two studies that may account for this. First, the previous study measured 24-hour
voluntary ethanol consumption while the present experiment utilized the limited access DID
procedure to model binge-like ethanol consumption. Previous studies have reported that
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separate neurocircuits may be involved in voluntary versus binge consumption. For
example, voluntary consumption engages the reward pathway (Koob et al., 1998; Volkow
and Li, 2004) while binge consumption likely recruits stress circuits (Koob, 2008; Lowery-
Gionta et al., 2012; Sparta et al., 2008) in addition to the reward pathway. Thus, it is
possible that MC3Rs are involved in the modulation of excessive binge-like ethanol
drinking but not moderate levels of ethanol intake that are characteristic of voluntary ethanol
consumption procedures. More importantly, our study used multiple doses (0.25, 0.5 and 1.0
μg) of MTII while only one dose (1.0 μg) was used previously. Even in the current report,
genotype differences in MTII sensitivity could have easily missed been as the highest dose
of MTII blunted binge-like ethanol drinking in both genotypes, at least at the 1-hour
measure (Fig. 1A). It is not until all of the doses of MTII are taken into account that a
pattern emerges that indicates loss of the MC3R augments the protective effects of MTII.
Given the involvement of the MC system in feeding behavior, these data further underscore
the overlapping pathways involved in alcohol and food consumption. Indeed, it has
previously been demonstrated that, in addition to suppressing alcohol consumption,
treatment with centrally-administered MTII in doses used here (0.5 or 1.0 μg) also reduced
the consumption of food, sucrose solution (caloric reinforcers) and saccharin solution (a
salient non-caloric reinforcer), but not water drinking (Navarro et al., 2005; 2011). These
observations are consistent with the idea that the central MC system modulates the
consumption of natural reinforcers (food and sweet solutions) and ethanol, regardless of
caloric content. Moreover, a wealth of neurochemical systems involved in both alcohol and
food consumption have already been identified (See Thiele et al., 2003 for review). A
multitude of clinical reports have described a relatively high rate of co-morbidity between
alcohol abuse and eating disorders (Dansky et al., 2000; Higuchi et al., 1993; Holderness et
al., 1994), which is not surprising considering both conditions involve aberrant
consummatory behavior and a loss of control. Moreover, in patients presenting both
alcoholism and eating disorders, it is often found that successful treatment of one disorder
also proves to be efficacious to both conditions (Daniels et al., 1999; Dawe and Staiger,
1998). Given these circumstances, examination of therapeutic drugs that act on these shared
neurochemical systems, such as the melanocortin system, may prove to be a worthwhile
endeavor.
5. Conclusions
In summary, we have demonstrated a possible role for the MC3R in modulating binge-like
ethanol consumption. Specifically, the MC3R appears to oppose the protective effects of
MTII against binge-like ethanol drinking, which may indicate that the MC3R serves as an
autoreceptor that prevents the release of endogenous α-MSH, or as a postsynaptic receptor
that functionally opposes the downstream actions of the MC4R. It will be important for
future studies to further characterize the contribution of the MC3R in modulating ethanol
consumption. The current observations suggest that MC3R antagonists may have therapeutic
value in combating alcohol abuse disorders, and may augment the ability of MC4R agonists
to protect against binge drinking.
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Ethanol consumed (g/kg) among MC3R−/− and MC3R+/+ mice during the first hour (A), and
total four hours (B) of the binge-like ethanol consumption, as well as BEC (mg/dl) measured
immediately at the end of the 4-hour test (C). During the first hour, MC3R−/− mice
displayed a reduction in binge-like ethanol drinking at all doses tested. Alternatively,
significant reductions in drinking were only observed following treatment with the highest
dose (1.0 μg) of MTII in MC3+/+ mice. Similarly, at the end of the 4-hour test, only the
highest dose of MTII caused a reduction in binge-like ethanol drinking in MC3R−/− mice.
No significant effect of MTII was observed on BEC regardless of genotype. Data are
presented as mean ± SEM. * signifies p < .05 relative to vehicle within that genotype.
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